HALF-LIFE FACTOR CONCENTRATES
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia Consortium.
-
Héma-Québec tender selects an extended half-life FVIII
Héma-Québec announced on November 30, following its Request for Proposals for recombinant factor VIII concentrates, that it had selected Esperoct. Esperoct is approved by Health...
-
No change to factor IX product mix in Quebec
Montreal, August 15, 2022 – On July 15, Héma-Québec announced the results of the recombinant factor IX tender for the period from October 1, 2022...
-
Hearing the patient voice on therapy choice: FVIII or non-FVIII
by the Canadian Association of Nurses in Hemophilia Care – Ontario Region* and Sarah Crymble, Ontario Hemophilia Provincial Coordinator Treatment for patients with hemophilia A...
-
CBS supplier contracts for rFVIII and rFIX take effect April 4
March 30, 2022, Ottawa – Canadian Blood Services’ contracts with suppliers of recombinant factor VIII and IX for the 2022-2025 period take effect on April...